PL2066314T3 - Zastosowanie teogaliny do leczenia umysłowych zaburzeń zdolności do koncentracji, depresji i demencji - Google Patents

Zastosowanie teogaliny do leczenia umysłowych zaburzeń zdolności do koncentracji, depresji i demencji

Info

Publication number: PL2066314T3
Authority: PL; Poland
Prior art keywords: theogallin; dementia; depression; treatment; mental concentration
Prior art date: 2006-09-26

Application number

PL07818393T

Other languages

English (en)

Inventor

Adolf Kler

Reinhold Zenger

Wilfried Dimpfel

Original Assignee

Plantextrakt Gmbh&Co Kg

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-26

Filing date

2007-09-25

Publication date

2014-05-30

2007-09-25 Application filed by Plantextrakt Gmbh&Co Kg filed Critical Plantextrakt Gmbh&Co Kg

2014-05-30 Publication of PL2066314T3 publication Critical patent/PL2066314T3/pl

Links

LDPLFHGGZNSKDS-AQWVNGNSSA-N 3-O-Galloylquinic acid Natural products O=C(O[C@H]1[C@@H](O)[C@H](O)C[C@@](O)(C(=O)O)C1)c1cc(O)c(O)c(O)c1 LDPLFHGGZNSKDS-AQWVNGNSSA-N 0.000 title 1
206010012289 Dementia Diseases 0.000 title 1
VLVOZOYAJUACSG-UHFFFAOYSA-N Theogallin Natural products COc1cc(cc(OC)c1OC)C(=O)OC2CC(O)(CC(O)C2O)C(=O)O VLVOZOYAJUACSG-UHFFFAOYSA-N 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
230000036649 mental concentration Effects 0.000 title 1
LDPLFHGGZNSKDS-FTBFGRRBSA-N theogallin Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)C1=CC(O)=C(O)C(O)=C1 LDPLFHGGZNSKDS-FTBFGRRBSA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

PL07818393T 2006-09-26 2007-09-25 Zastosowanie teogaliny do leczenia umysłowych zaburzeń zdolności do koncentracji, depresji i demencji PL2066314T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE102006045764A DE102006045764A1 (de)	2006-09-26	2006-09-26	Verwendung von Theogallin zur Herstellung eines Arzneimittels zur Prophylaxe und Behandlung von neurologischen und psychiatrischen Erkrankungen des zentralen Nervensystems, insbesondere von mentalen Konzentrationsleistungsstörungen, Depression und Demenz
EP07818393.6A EP2066314B1 (de)	2006-09-26	2007-09-25	Verwendung von theogallin zur behandlung von mentalen konzentrationsleistungsstörungen, depression und demenz
PCT/EP2007/008308 WO2008037416A2 (de)	2006-09-26	2007-09-25	Verwendung von theogallin zur behandlung von mentalen konzentrationsleistungsstörungen, drepression und demenz

Publications (1)

Publication Number	Publication Date
PL2066314T3 true PL2066314T3 (pl)	2014-05-30

Family

ID=39134217

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL07818393T PL2066314T3 (pl)	2006-09-26	2007-09-25	Zastosowanie teogaliny do leczenia umysłowych zaburzeń zdolności do koncentracji, depresji i demencji

Country Status (5)

Country	Link
EP (1)	EP2066314B1 (pl)
DE (1)	DE102006045764A1 (pl)
ES (1)	ES2443222T3 (pl)
PL (1)	PL2066314T3 (pl)
WO (1)	WO2008037416A2 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT202200000581A1 (it) *	2022-01-17	2023-07-17	Univ Degli Studi Di Verona	Acido chinico per l'uso nel trattamento dei disturbi dell'umore - Quinic acid for use in the treatment of mood disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8496914B2 (en) *	2005-12-13	2013-07-30	Richard Paul Bonfiglio	Antibacterial oral rinse formulation for preventing coronary artery disease

2006
- 2006-09-26 DE DE102006045764A patent/DE102006045764A1/de not_active Withdrawn
2007
- 2007-09-25 ES ES07818393.6T patent/ES2443222T3/es active Active
- 2007-09-25 EP EP07818393.6A patent/EP2066314B1/de active Active
- 2007-09-25 WO PCT/EP2007/008308 patent/WO2008037416A2/de not_active Ceased
- 2007-09-25 PL PL07818393T patent/PL2066314T3/pl unknown

Also Published As

Publication number	Publication date
WO2008037416A2 (de)	2008-04-03
DE102006045764A1 (de)	2008-04-03
ES2443222T3 (es)	2014-02-18
WO2008037416A3 (de)	2008-06-12
EP2066314A2 (de)	2009-06-10
EP2066314B1 (de)	2013-12-04

Similar Documents

Publication	Publication Date	Title
IL195906A0 (en)	2009-09-01	Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
AP2011005672A0 (en)	2011-04-30	Pyrazolopyrimidines and their use for the treatment of CNS disorders.
ZA200806114B (en)	2009-11-25	Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
IL195819A0 (en)	2009-09-22	Modulators of metabolism and the treatment of disorders related thereto
IL195851A0 (en)	2009-09-01	Modulators of metabolism and the treatment of disorders related thereto
IL187168A0 (en)	2008-02-09	Improved nanobodiestm for the treatment of aggregation-mediated disorders
IL186447A0 (en)	2008-08-07	Methods for the treatment of substance abuse and dependence
IL179508A0 (en)	2007-05-15	2-substituted-4- heteroaryl-pyrimidines useful for the treatment of proliferative disorders
EP1874286A4 (en)	2009-07-01	METHOD AND COMPOSITIONS FOR TREATING ANXIETY STATE
EP2278972A4 (en)	2011-09-07	TREATMENT FOR NEUROLOGICAL AND MENTAL DISORDERS
ZA200901523B (en)	2010-05-26	Use of extracts for the treatment of viral disorders
IL188390A0 (en)	2008-04-13	Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders
ZA200801667B (en)	2009-03-25	Novel pharmaceutical combinations for the treatment of respiratory disorders
PL1890684T3 (pl)	2014-05-30	Leczenie zaburzeń snu i czuwania
IL189009A0 (en)	2008-11-03	Methods and compositions for the treatment of neuropathies and related disorders
IL198134A (en)	2017-02-28	A combination of antipsychotic drugs and tetracyclines to treat psychiatric illnesses
GB0610350D0 (en)	2006-07-05	prevention and/or treatment of neuodegenerative disorders
IL193697A0 (en)	2009-08-03	Methods for treating cognitive and other disorders
HUE050758T2 (hu)	2021-01-28	Glutamátmoduláló szerek mentális rendellenességek kezelésére
EP2004216A4 (en)	2012-02-01	AGENT FOR THE TREATMENT OF HORMONO-DEPENDENT DISORDERS AND USES THEREOF
IL200570A0 (en)	2010-05-17	Combination therapy, composition and methods for the treatment of cardiovascular disorders
IL197766A0 (en)	2009-12-24	Use of oritavancin for the prevention and treatment of anthrax
ZA200709443B (en)	2009-08-26	Methods for the treatment of substance abuse and dependence
IL181777A0 (en)	2007-07-04	Gpr43 and modulators thereof for the treatment of metabolic-related disorders
GB0710277D0 (en)	2007-07-11	Use of antivirals in the treatment of medical disorders